TNF-α targeted therapeutic approaches in patients with hematologic malignancies

Expert Review of Anticancer Therapy

Volumn 2, Issue 3, 2002, Pages 277-286

  Tsimberidou, Apostolia Maria ^a   Giles, Francis J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

AntiTNF therapy; Etanercept; Hematologic malignancies

Indexed keywords

ADALIMUMAB; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOKINE; CYTOTOXIC AGENT; D 2E7; DAUNORUBICIN; DEXAMETHASONE; ETANERCEPT; HYPER CVXD; INFLIXIMAB; LENERCEPT; MELPHALAN; METHOTREXATE; PENTOXIFYLLINE; PROTEIN P55; PROTEIN P75; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG; VINCRISTINE;

ABDOMINAL CRAMP; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIBODY PRODUCTION; CANCER IMMUNOTHERAPY; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE MYELOMA; MYALGIA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NEUROLOGIC DISEASE; PANCYTOPENIA; PATHOGENESIS; PLEIOTROPY; PROTEIN FUNCTION; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; UPPER RESPIRATORY TRACT INFECTION;

EID: 0036081009     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.2.3.277     Document Type: Review

References (96)

1. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins
2. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor
3. Isolation and characterization of a tumor necrosis factor binding protein from urine
4. Tumor necrosis factor signal transduction. Tissue-specific serine phosphorylation of a 26-kDa cytosolic protein
5. TNF-α and the TNF receptor superfamily: Structure-function relationship(s)
6. Tumor necrosis factor is a survival and proliferation factor for human myeloma cells
7. Multiple myeloma: Increasing evidence for a multistep transformation process
8. The role of the two TNF receptors in proliferation, NF-κB activation and discrimination between TNF and LT α signalling in the human myeloma cell line OH-2
9. New insight in the clinical biology of multiple myeloma
10. Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors
11. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes
12. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes
13. Cytokine gene activity in AML cells in vivo in patients
14. Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage
15. An unusual cause of progressive heart disease
16. Treatment of the nephrotic syndrome with etanercept in patients with the tumor necrosis factor receptor-associated periodic syndrome
17. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease
18. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation
19. Tumor necrosis factor-alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease
20. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies
21. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation
22. Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor-α (TNF-α) release in the course of pretransplant conditioning: Role of conditioning regimens application of a monoclonal antibody neutralizing human TNF-α (MAK 195F)
23. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists
24. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter Phase III trial with 1,342 patients
25. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
26. CDP571, a humanized antibody to human tumor necrosis factor-α: Safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock
27. The engineered human anti-tumor necrosis factor-α antibody CDP571 inhibits inflammatory pathways but not T cell activation in patients with rheumatoid arthritis
28. Effects of treatment with a fully human anti-tumour necrosis factor-α monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNF-α in patients with rheumatoid arthritis
29. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation
30. Aza analogues of thalidomide: Synthesis and evaluation as inhibitors of tumor necrosis factor-α production in vitro
31. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway
32. Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS
33. Potential role for phosphatidic acid in mediating the inflammatory responses of TNF-α and IL-1β
34. Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes
35. Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone
36. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
37. Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome
38. Soluble tumor necrosis factor receptor (p75) fusion protein (etanercept) as a therapy for rheumatoid arthritis
39. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis
40. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
41. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
42. Etanercept in children with polyarticular juvenile rheumatoid arthritis
43. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial
44. Recombinant human soluble tumor necrosis factor (TNF) receptor (P75) fusion protein (TNFR:Fc)(etanercept) in patients with refractory multiple myeloma
45. Combination of Thalidomide and etanercept for the Treatment of Patients with Myelodysplastic Syndromes (MDS)
46. Effect of in vitro administration of TNF receptor fusion protein (TNFR:Fc) on the biological characteristics of AML cells
47. In vivo administration of TNFR:Fc to acute myeloid leukemia patients: Preliminary data on safety and changes in blood and bone marrow
48. Recombinant human soluble tumor necrosis factor receptor (P75) fusion protein (TNFR:Fc) (etanercept) in patients with refractory hematological malignancies
49. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease
50. Inhibitors of tumor necrosis factor for rheumatoid arthritis
51. Etanercept and urticaria in patients with juvenile idiopathic arthritis
52. Etanercept (etanercept): Update on therapeutic use
53. Etanercept combined with conventional treatment in Wegener's granulomatosis: A six-month open-label trial to evaluate safety
54. Results of targeted anti-tumor necrosis factor therapy with etanercept (etanercept) in patients with advanced heart failure
55. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (etanercept, etanercept) in patients with advanced heart failure
56. Anti-TNF-α therapy of rheumatoid arthritis: What have we learned?
57. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: A recombinant tumor necrosis factorα receptor: Fc fusion protein
58. Demyelination occurring during anti-tumor necrosis factor-α therapy for inflammatory arthritides
59. Onset of multiple sclerosis associated with anti-TNF therapy
60. Cancer statistics
61. Patients receiving etanercept may develop antibodies that interfere with monoclonal antibody laboratory assays
62. Etanercept-induced injection site reactions: Mechanistic insights from clinical findings and immunohistochemistry
63. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration
64. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The soluble TNF Receptor Sepsis Medicine
65. TNF and IL-6 are potent growth factors for OH-2, a novel human myeloma cell line
66. Autocrine growth by two cytokines, interleukin-6 and tumor necrosis factor-α, in the myeloma cell line KHM-1A
67. Cytokines (IL-6, TNF-α, IL-1α) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma
68. Apoptosis-induced by TRAIL and TNF-α in human multiple myeloma cells is not blocked by BCL-2
69. An interleukin 1 like factor stimulates bone resorption in vitro
70. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors
71. Production of cytokines by bone marrow cells obtained from patients with multiple myeloma
72. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival
73. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
74. Myelodysplasia
75. Indication of an involvement of interleukin-1β converting enzyme-like protease in intramedullary apoptotic death in the bone marrows of patients with myelodysplastic syndromes
76. Report of an international working group to standardize response criteria for myelodysplastic syndromes
77. Pentoxyphylline prevents tumor necrosis factor-induced lung injury
78. Transfer of tumor necrosis factor-α to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-beta1 and myofibroblasts
79. Transient expression of IL-1β induces acute lung injury and chronic repair leading to pulmonary fibrosis
80. TNF-α, PDGF, and TGF-β(1) expression by primary mouse bronchiolar-alveolar epithelial and mesenchymal cells: TNF-α induces TGF-β(1)
81. Gene expression of tumor necrosis factor-α and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients
82. Tumor necrosis factor/cachectin and lymphotoxin gene expression in lymph nodes from lymphoma patients
83. Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: Results of a pilot study
84. The tumor necrosis factor family and correlation with disease activity and response to treatment in hairy cell leukemia
85. TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies
86. Tumor necrosis factor modulates CD 20 expression on cells from chronic lymphocytic leukemia: A new role for TNFα?
87. Endotoxin-induced cytokine gene expression in vivo. IL-6 mRNA and serum protein expression and the in vivo hematologic effect of IL-6
88. Successful treatment of Langerhans'-cell histiocytosis with etanercept
89. TNF receptor p55 controls early acute graft-versus-host disease
90. Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease
91. Infliximab for the treatment of graft-versus-host disease in allogeneic transplant recipients: An update
92. Salvage therapy with infliximab for patients with severe acute and chronic GvHD
93. Treatment of severe steroid refractory acute graft versus host disease with Infliximab
94. Etanercept in graft-versus-host disease
95. Total body irradiation and acute graft-versus-host disease: The role of gastrointestinal damage and inflammatory cytokines